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Screening has a central role in colorectal cancer (CRC) control. Different screening tests
are effective in reducing CRC-specific mortality. Influence on cancer incidence depends on
test sensitivity for pre-malignant lesions, ranging from almost no influence for guaiac-based
fecal occult blood testing (gFOBT) to an estimated reduction of 66–90% for colonoscopy.
Screening tests detect lesions indirectly in the stool [gFOBT, fecal immunochemical testing
(FIT), and fecal DNA] or directly by colonic inspection [flexible sigmoidoscopy, colonoscopy,
CT colonography (CTC), and capsule endoscopy]. CRC screening is cost-effective compared
to no screening but no screening strategy is clearly better than the others. Stool tests are
the most widely used in worldwide screening interventions. FIT will soon replace gFOBT.
The use of colonoscopy as a screening test is increasing and this strategy has superseded
all alternatives in the US and Germany. Despite its undisputed importance, CRC screen-
ing is under-used and participation rarely reaches 70% of target population. Strategies to
increase participation include ensuring recommendation by physicians, introducing orga-
nized screening and developing new, more acceptable tests. Available evidence for DNA
fecal testing, CTC, and capsule endoscopy is reviewed.
Keywords: colorectal cancer, advanced adenoma, screening, flexible sigmoidoscopy, total colonoscopy, fecal tests,
CT colonography, capsule endoscopy
ROLE OF SECONDARY PREVENTION IN COLORECTAL CANCER
CONTROL
Screening has a central role in colorectal cancer (CRC) control.
Even if incidence studies show that the majority of large bowel can-
cers are sporadic, few protective and risk factors for the disease have
been consistently identified so far (e.g., alcohol, red and processed
meat intake, obesity, smoking, physical activity, and aspirin use)
(1). Modifiable factors are associated with slightly elevated risks of
developing CRC, in most cases between 1.2 and 2.0. Some estab-
lished risk factors are widely diffused in the general population
so that they are responsible for a substantial share of disease bur-
den and, thus, are potential targets for preventive interventions
(2). However, changing dietary habits and physical activity lev-
els is difficult. Typically, the Western lifestyle is associated with
an unfavorable pattern of risk factors and with high CRC inci-
dence rates (3, 4) and these, together with mortality trends, are
also reported in developing countries (5, 6). CRC prognosis has
slowly been improving (7). Progress has been made in the treat-
ment of the disease, particularly for rectal cancer (8). However,
both advanced age and stage at diagnosis limit the opportunity for
curative treatment in many cases (9). Diagnosis at earlier stages in
disease development has led to a dramatic change in prognosis and
to more conservative treatment (10). Thus, screening is presently
the key intervention for CRC control.
DISEASE IS SUITABLE FOR SCREENING
Colorectal cancer is an ideal target for screening interventions (11).
Colorectal cancer is an important health burden. With 746,000
cases in males (10.0% of total cancer cases) and 614,000 cases
in women (9.2% of total), large bowel cancer is estimated to be
the third (following lung and breast cancer) most frequent can-
cer worldwide in both sexes combined (12). In western countries,
CRC is the most frequent cancer in both sexes (13). CRC is also a
leading cause of cancer death, ranking fourth after lung, liver, and
stomach cancer (12).
In the majority of cases, the disease develops over many years
through the so-called adenoma–carcinoma sequence (14). Detec-
tion and removal of pre-malignant lesions can prevent progression
to cancer and decrease incidence (15–18). CRC, as with many other
cancers, is curable in most cases if detected at an early stage (10).
COLORECTAL CANCER SCREENING TESTS
Screening tests are available to detect pre-malignant lesions and
cancer at early stages. Screening tests are classified in two groups:
(i) indirect tests looking for the presence of markers of colorec-
tal neoplasm in the stool; (ii) tests based on direct visualization of
neoplasm in the large bowel. Currently, both stool-based [i.e., fecal
occult blood test (FOBT) and fecal immunochemical test (FIT)]
and endoscopy-based tests [i.e., flexible sigmoidoscopy (FS) and
total colonoscopy (TC)] are almost exclusively used in ongoing
opportunistic and organized CRC screening worldwide.
There is evidence from randomized controlled trials (RCT)
and meta-analyses that guaiac-based [guaiac-based fecal occult
blood testing (gFOBT)] and FS screening decrease CRC-specific
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mortality (15, 19). FIT shares the same indirect target for the pres-
ence of colorectal neoplasm with gFOBT; that is, the presence of
blood in the stool. There is sufficient evidence that FIT outper-
forms gFOBT in terms of sensitivity (20, 21) and compliance with
invitation (22). There is no available evidence from RCTs support-
ing the efficacy of colonoscopy as a CRC screening test and results
from the ongoing RCTs will take decades to appear (23–25). How-
ever, TC is considered an effective screening test for CRC based
on the following arguments: (i) evidence available for FS applies
to TC as well since both tests are based on direct visualization of
intestinal lumen; (ii) mortality reduction achieved with FOBT tests
depends on colonoscopy as the confirmatory test; and (iii) avail-
able observational studies confirm that TC is highly effective in
reducing CRC mortality and incidence (26). CRC screening is also
cost-effective if compared to no screening (27, 28). Screening tests
currently in use have recently been reviewed in detail (15, 21, 29).
GUAIAC-BASED FECAL OCCULT BLOOD TEST
Four large RCTs (30–33) showed that a screening program based
on a gFOBT repeated every 1 or 2 years reduces CRC-specific
mortality by 16% (up to 23% according to the per-protocol
analysis) (34).
Some characteristics of gFOBT may limit compliance: they
must be collected from three consecutive stools and they are
sensitive to diet intake of hemoglobin (35). This led to the indi-
cation of dietetic restrictions at the price of loss in compliance;
diet indications were subsequently dropped because of limited
clinical significance (36–39). gFOBT is also sensitive to bleeding
of the upper gastro intestinal (GI) tract (40). A further limita-
tion of gFOBT is its low sensitivity for CRC (25–38%) and for
advanced adenomas (AA) (16–31%) (20), the latter probably being
the reason for the lack of incidence reduction among screened
populations (34). Test sensitivity may be increased by rehydrating
the test windows before development (41), but this significantly
affects specificity (39, 42). Since the reading of the test is not auto-
mated, an inter-operator as well as a batch-to-batch variability has
been reported (39). gFOBT is more stable than FIT if exposed to
high temperature (43).
FECAL IMMUNOCHEMICAL TEST
No RTC on the impact of FIT-based screening on CRC mortal-
ity has been carried out. A recent ecological study showed a 22%
reduction in CRC-specific mortality in areas where FIT screen-
ing programs were active compared to controls (44). The impact
of screening with FIT on incidence rates has also been reported
(18). Further evidence of FIT test efficacy is indirect, based on a
large number of trials comparing performance of different FIT
tests with gFOBT (45–54). These studies are difficult to compare
because they used different positivity cut-offs and different sam-
ple numbers (51–53, 55). Overall sensitivity of FIT is higher than
gFOBT both for CRC (61–91%) and for AA (27–67%) and the
test has a comparable specificity (ranging from 91 to 98% versus
98–99%) (40).
Fecal immunochemical tests are specific for human blood and
insensitive to upper GI bleeding (21). There are qualitative FIT
tests that produce a binary result (positive or negative), whose
positivity cut-off may not be adjusted and whose reading is not
automated. Their performance showed a large variability among
manufacturers (56). Quantitative FIT produce a quantitative result
of the fecal hemoglobin concentration, generally as nanograms
of hemoglobin per milliliter buffer added and whose positivity
cut-off may be adjusted.
The best number of samples and the positivity cut-off have not
yet been defined and this uncertainty reflects on recommenda-
tions published in different countries (45, 50, 57–60). However,
complicated stool handling may negatively affect screening com-
pliance; according to two studies, 60–62% with 1-sample FIT
versus 47–50% with three-samples gFBOT (50, 52). In addition,
recent findings show that increasing the number of FIT samples
does not affect the main performance indicators of FITs for CRC
(61). It is thus reasonable to use a single sampling and to act on
the cut-off to adjust the desired sensitivity (22, 62). Some trials
have identified a protocol based on a single sample with a positiv-
ity cut-off of 75 ng/ml as a good trade-off between sensitivity and
specificity (49, 63–65). Storage conditions (e.g., excessive tempera-
ture) may increase false-negative rates (64) and require technology
solutions by the manufacturers. According to some recent studies,
FIT is the most cost-effective tool for CRC screening (66–68) with
a sensitivity (76%) and a specificity (95%) comparable to TC (24).
The European Guidelines recommend FIT for programs adopt-
ing a strategy based on fecal occult blood test (21).
FLEXIBLE SIGMOIDOSCOPY
Randomized controlled trials showed that screening with FS
reduces CRC mortality by 22–31% and incidence by 18–23%
through visual inspection of colic mucosa, biopsy taking and
polyp removal in the distal tract of colon (69–71). A population-
based trial showed similar results after a median follow up of
10.9 years (72).
The impact of screening with FS on incidence and mortal-
ity rates is limited to the distal colon, while RCTs showed no
significant differences as regards the distal tract. A combined strat-
egy using FS and gFOBT/FIT did not seem to solve the problem
(72, 73) while it would increase endoscopic workload and reduce
participation (72, 74, 75).
Overall, FS is a safe test: very low complication rates (mainly
perforations and bleeding requiring transfusion) have been
reported (76).
TOTAL COLONOSCOPY
Total colonoscopy allows direct visualization of the colonic
mucosa, biopsy of lesions, and polyp removal over the whole colon.
Sensitivity and specificity for CRC and AA are very high, even if a
miss-rate of CRC of between 0.2 and 5.0% was reported (77–82).
TC is the confirmatory test used in case of a positive test for all the
above screening strategies (21, 42, 83).
Evidence of efficacy derives from observational studies, show-
ing a relevant impact on incidence (reduced by 66–90% compared
to the general population) and mortality (31–65%) (16, 84–87).
Total colonoscopy as a CRC screening test is not free from
limits. A high inter-operator variability in the adenoma detection
rate has been reported and this feature has been associated with
the subsequent risk of CRC (88). Moreover, retrospective analy-
ses questioned the capability of reducing incidence and mortality
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from proximal CRC in community settings (89, 90). Thus, proper
training programs for endoscopists are necessary, as well as con-
tinuous quality assurance (91). Collateral effects of TC are rare but
more frequent than with FS (20).
Many characteristics negatively affect the acceptability of TC
as a first-line screening test: it is an invasive examination, which
requires an even more invasive bowel cleansing and it is time-
consuming, expensive, and painful. Even if in the US the uptake
of TC is increasing (92), in the EU countries compliance has been
very low (93).
GEOGRAPHIC DISTRIBUTION OF CRC SCREENING
Diffusion of CRC screening shows a marked geographic variation
(94). Screening is more frequently available in high incidence, high
resources western countries. CRC screening practices in Europe
have recently been reviewed by Altobelli et al. (13). Stool-based
tests are more used than endoscopy. gFOBT is the recommended
test in many countries like UK, France, and Finland. FIT is the test
of choice in Spain, the Netherlands, and in most Italian programs.
Screening is mainly national and programed in European coun-
tries and includes the 50–74 age group as the target population.
Opportunistic screening is diffused in Austria and Germany, and,
outside Europe, in Japan, Australia, and Canada (95). Germany,
Poland, and the US adopt TC as CRC screening test, alone or as
an alternative to other possible test choices. The US has a long-
standing history of CRC screening dating back to the 80s. CRC
screening in the US is not diffused in the form of organized pro-
grams but different test choices are equally recommended [i.e.,
(1) annual high-sensitivity gFOBT or FIT, following the manu-
facturer’s recommendations for specimen collection; (2) FS every
5 years; (3) TC every 10 years; (4) double-contrast barium enema
every 5 years; or (5) CT colonography (CTC) every 5 years] (96).
However, TC has progressively become the most widely used test
in the US and is increasingly considered the gold standard test for
CRC screening because of the claimed effectiveness in detecting
cancer and advanced pre-malignant lesions in comparison with
stool-based tests that primarily detect cancer at early stages (97–
99). The preference of TC as a CRC screening test in the US
is largely attributable to the classification of stool-based tests as
aimed primarily at detecting cancer and as a test based on struc-
tural examination of large bowel as aimed at detecting both cancer
and advanced pre-malignant lesions (96).
SCREENING STRATEGIES
Studies agree that at present there is no clear evidence of the supe-
riority of one screening test and strategy over the others (28, 99).
High variability of screening interventions worldwide reflects
this situation. Determinants of the adoption of screening strate-
gies include: (i) test performance and, in particular, ability to
detect pre-malignant lesions and decrease incidence of invasive
cancer; (ii) acceptability of tests and screening participation; and
(iii) resource needs associated with different strategies.
Fecal immunochemical test is increasingly considered a better
test than gFOBT because of better accuracy, compliance, and cost-
effectiveness (100). Moreover, FIT showed better sensitivity than
gFOBT for advanced neoplasia and this feature should also result
in a larger decrease of CRC incidence (18, 19, 101).
Among tests based on large bowel structural examination,
TC is the preferred test, despite high costs and invasiveness. In
particular, in the US, TC has progressively gained the widest dif-
fusion over the other available tests, including FS (97). Endoscopy
tests showed better sensitivity than FIT for the diagnosis of pre-
malignant polyps and, particularly, advanced neoplasia. Thus,
endoscopy tests are likely to confer better individual protection
and have a stronger influence on cancer incidence if compared
to FIT (17, 102). However, FIT is a better accepted screening test
than FS and TC. Thus higher participation in screening using
FIT may, to some extent, balance lower sensitivity than endoscopy
tests (103–105).
Recent studies comparing FIT to endoscopy tests in a single
screening round confirmed that FIT is associated with the highest
participation (23, 101). Higher participation rates achieved by FIT
reduce, but do not eliminate the gap in detection rate of cancer and
AA compared to endoscopy tests. However, screening strategies
using FIT have typically shorter intervals between subsequent test
repetition that should further reduce or even reverse the difference
in detection rates with respect to FS and TC (101). Results of stud-
ies comparing endoscopy tests with repeated rounds using FIT will
depend on both test sensitivity and compliance with subsequent
invitation in the FIT group (106, 107).
The diagnosis of pre-malignant lesions and consequent
decrease of incident cancers is a much desirable feature of CRC
screening. The concept of over-diagnosis apparently does not
apply to CRC screening since a steeply increasing incidence does
not follow screening introduction and, on the contrary, a decreas-
ing incidence trend is reported in the US, after decades of CRC
screening progressive diffusion (97). However, the concept of
over-diagnosis in CRC should also be tested against incidence of
pre-malignant lesions. In particular, the rate of colectomies should
be monitored and compared among different screening tests and
to non-screened groups or populations.
In conclusion, FIT testing is increasingly the most used CRC
screening strategy. In a few countries, including US and Germany,
TC is recommended and is the most used test. Cost and availability
of endoscopy resources may be the limiting factors in the adoption
of TC screening strategy.
IMPROVING OUTCOMES IN CRC SCREENING
Improvement of CRC screening is a much desirable aim that is
actively pursued through research to improve performance of tests
and strategies to increase screening participation.
Despite its central role in CRC control and the availability of a
range of effective tests, CRC screening is typically under-used. In
the US participation in CRC screening has been increasing since
its introduction in the 80s but was still below 70% in 2010 (97). In
European countries, screening started much more recently than in
the US and participation rates are generally lower than in US (13).
Strategies to improve participation in screening interventions
were reviewed by Jepson et al. (108) and, more recently, by Camil-
loni et al. (109). The implementation of organized interventions
may improve participation and reduce inequalities in screening
uptake if compared to opportunistic screening (11). This strat-
egy has been adopted in many European countries and is actively
considered in Germany and US (13, 110, 111).
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Physician recommendation influences participation (112).
Sequential offering of available screening tests may contribute to
maximize participation (113, 114). Research on screening tests
with improved features including better acceptability is ongoing
and serum markers represent a possible example of acceptable
screening tests (115).
Better diagnostic performance is another way to improve
CRC screening outcomes. Performance could be improved
through: (i) strategies based on the combination of existing tests
or (ii) improvement of screening tests that can be achieved with:
(1) improvement of existing tests, (2) introduction of new diag-
nostic tests. CRC screening strategies currently in use consist
either in opportunistic screening allowing individual selection
of a test among many recommended alternatives or in orga-
nized screening based on the administration of a single type
of test. The combination of tests with different features may
be investigated to improve performance. Combination of FIT
and FS has been discussed above. A simulation model showed
that FIT at younger age combined with colonoscopy at older
ages may represent a cost-effective alternative to single test
strategies (116).
Research is continuously being done to improve existing tests
or develop new ones. FIT can be considered an improvement of
the older stool-based test gFOBT (100). As an example of inno-
vation of existing tests, full-spectrum TC has recently been shown
to have higher sensitivity for colorectal adenomas than traditional
TC (117). Many new tests are currently in development. We briefly
review tests that have been used or are ready for field use.
FECAL DNA TESTING
Fecal sample testing using molecular diagnostic tests is emerging
as a potentially important new approach. There is a strong biologic
rationale to pursue this technology, given that adenoma and can-
cer cells that contain altered DNA are continuously shed into the
large bowel lumen. DNA is stable in the feces and it can therefore
be extracted for analysis. Due to the heterogeneity of cancer, no
single molecular marker has shown an optimal sensitivity, while
panels of different markers in early studies have allowed a higher
detection rate for both CCR and AA.
However, observations on larger size population studies
appeared less encouraging, showing only fair sensitivity for the
detection of CRC and low sensitivity for the detection of AA (118,
119). Significant technical improvements have been carried out
in recent years, which have raised sensitivity of these tests for the
detection of colonic lesions.
A very recent study by Imperiale (120) compared a multi-
target stool DNA test with a commercial FIT among a large series
of subjects at average-risk for CRC. The sensitivity of the DNA
test for the detection of both CRC (92.3%) and advanced pre-
cancerous lesions (42.4%) was very impressive, being superior to
that of FIT by a difference of about 20% points, even if FIT was
more specific for CRC and advanced precancerous lesions (120).
A higher rate of non-adequate samples respect to FIT (6.3 ver-
sus 0.3%) was also registered. DNA fecal testing is an addition
to the stool-based tests for CRC screening but further studies are
needed to understand whether stool DNA testing has any role in
CRC organized screening, taking into account other key factors
yet to be assessed, such as the screening interval, adherence, and
costs.
Clinical proteomics is an emerging issue in cancer research.
Potentially, blood proteomics tests in the near future will be
able to detect patterns of proteins associated with cancer or
low molecular-weight compounds related to an abnormal cell
growth. In the words of Liotta and Petricoin (121) “the low-
molecular-weight region of the blood proteome is a treasure trove
of diagnostic information ready to be harvested by nanotechnol-
ogy.” Unfortunately, no clinical applications are available at the
moment and large multicenter studies in average-risk populations
are needed in order to fully understand the true potential of this
new biomolecular technology.
CT COLONOGRAPHY
CT colonography, or virtual colonoscopy, is a poorly invasive
radiological technique for imaging the large bowel. It provides
two-dimensional and three-dimensional images. A bowel insuffla-
tion with carbon dioxide is needed. If polyps or CRC are detected
on CTC, patients are referred to TC. CTC is well tolerated by
patients (122, 123) and it can be performed even with limited
bowel preparation. Several studies have demonstrated that CTC
has a high-sensitivity for the detection of colonic lesions that was
equal to 83–93% for polyps larger than 10 mm and to 60–86% for
intermediate polyps with a 6–9 mm in size (124–129). Specificity
of CTC resulted also very high for lesions>9 mm (95–97%) (125,
126, 128).
The risk of complications is extremely low, with no perfora-
tions or other serious complications in a large CTC screening
cohort (130).
CT colonography reading may be time-consuming for the
radiologist and this aspect is particularly interesting in a screen-
ing setting. Systems for helping radiologists in detecting colonic
lesions at CTC have been developed [Computer aided diagnosis
(CAD)]. Few data (131) suggest that this strategy has a sensitivity
for polyps similar to that with unassisted reading and allows for a
reduction in the reading time (132).
For these features, CTC could be a good alternative as primary
test in a screening setting.
A RCT conducted in the Netherlands (133) compared partici-
pation in a CRC screening setting with CTC or with TC, showing
that adherence of invited subjects was significantly better with
CTC than with TC. On the other hand, TC identified significantly
more advanced neoplasia per 100 participants than did CTC, even
if the diagnostic yield for advanced neoplasia per 100 invitees was
similar for both strategies.
In the perspective of including CTC as a screening test, some
considerations about potential disadvantages are needed:
• CTC-based screening may produce a high referral rate to
colonoscopy, with an increase of costs.
• Detection of extracolonic lesions: CTC displays the abdomi-
nal organs, thus the prevalence of extracolonic diseases that
require further investigation may be substantial (6% in asymp-
tomatic average-risk populations). Risks and costs associated
with false-positive results and unnecessary diagnosis should be
considered (134).
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• Exposure of individuals to ionizing radiation; the probability of
radiation-induced malignancy is very low, especially with low
dose protocols.
Two randomized clinical trials are underway in Italy comparing
CTC as primary test versus biennial FIT and versus TC (135) or
versus FS (136). Both these trials will provide reliable information
concerning participation/acceptability, diagnostic yield, and costs
of screening with CTC in comparison with FIT or FS. The trials
will also evaluate the role of CAD in a screening setting.
Pending the results of these studies, we currently have no avail-
able data about the effectiveness of CTC as primary test in CRC
screening.
However, organized screening programs have already intro-
duced CTC as a current complementary assessment for FIT pos-
itive patients with incomplete colonoscopy or with contraindica-
tions to colonoscopy (137).
The potential role of CTC as a first-line CRC screening strategy
is very attractive. In this setting, CTC may offer clear advantages,
such as accuracy, safety, and subject acceptance. Future research
will tell us whether this strategy might be a good option in terms of
participation, costs, and benefit/risks ratio for the CRC screening
programs.
COLON CAPSULE ENDOSCOPY
Colon capsule endoscopy, also called video or wireless capsule
endoscopy, is a relatively new technique to visualize the colon,
developed by Given Imaging Ltd. for small bowel imaging. In
2006, a first generation of capsule, dedicated to colon investiga-
tion [PillCam Colon capsule endoscopy (CCE)] was developed.
Images are transmitted to a computer workstation for the visual-
ization. In case of abnormalities detected by CCE, a colonoscopy
is needed to allow removal of polyps and subsequent pathologic
diagnosis. Patients have to undergo bowel cleansing before the
CCE. Bowel preparation is specifically designed not only to clean
the colon, but also to allow colonic distension and propel the cap-
sule through the colon. Even small amounts of residual stool may
influence visualization of the colonic mucosa (138).
One study evaluated the diagnostic accuracy of CCE in a
prospective setting with high-risk patients (139). Sensitivity and
specificity for detecting polyps ≥6 mm was 64 and 84%, respec-
tively, whereas sensitivity and specificity for advanced adenoma
detection was 73 and 79%, respectively. Recently, a second-
generation colon capsule (CCE-2) has been made available. The
new CCE measures 11.6 mm× 31.5 mm, with a widened angle
of view, thus allowing for nearly 360° coverage of the colon.
The device can adapt the image acquisition rate depending on
the speed of progression of the capsule along the colon. To
further save battery energy, CCE-2 can “choose” to work at a
low rate of 14 images per minute until small bowel images are
detected.
CCE-2 is provided with a new data recorder (DR3) endowed
with an artificial intelligence software. DR3 can communicate with
the capsule that listens to the “thinking” Data Recorder 3 and car-
ries out the orders received by it. Moreover, the DR3 guides the
medical staff and the patient through the procedure, buzzing, and
displaying instructions on its liquid crystal screen.
Two studies conducted in Israel (140) and in Italy (141)
have evaluated CCE-2 diagnostic accuracy for polyps. In the
first one, CCE-2 was prospectively compared with conventional
colonoscopy as the gold standard in a cohort of 98 patients with
known or suspected colonic disease. Per-patient CCE-2 sensitiv-
ity for polyps at least 6 mm in size was 89%, and at least 10 mm
in size was 88%, with specificities of 76 and 89%, respectively. In
the European trial, 109 patients were considered for analysis. Per-
patient CCE-2 sensitivity for polyps at least 6 mm in size was 84%
(95% CI 74–95%), and at least 10 mm in size was 88% (95% CI 76–
99%) with a specificity of 64 and 95%, respectively. Data regarding
diagnostic accuracy of the CCE-2 are encouraging, but evidence
concerning the diagnostic performance of this new technology is
in any case limited and based only on a few studies with a small
number of subjects recruited. Moreover, studies in an average-risk
screening population are still lacking. For this reason, a multicen-
ter prospective study is underway in Italy with the aim of assessing
the accuracy of PillCam colon 2 in a screening setting.
Colonic preparation for a colon capsule represents another
challenge. Recent studies evaluated a new protocol with a split-
dose PEG and a low dose of NaP, reporting good results (142).
In conclusion, the possible role of CCE as the primary test
in CRC screening represents a fascinating perspective, but fur-
ther studies are needed to understand the real impact of this new
technique in the non-invasive diagnosis of CCR and its precursors.
ACKNOWLEDGMENTS
We would like to thank Mrs. Catherine Brandt for English review.
REFERENCES
1. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet (2014) 383:1490–502.
doi:10.1016/S0140-6736(13)61649-9
2. Rose G. The Strategy of Preventive Medicine. Oxford: Oxford University Press
(1992).
3. Chan AT, Giovannucci EL. Primary prevention of colorectal cancer. Gastroen-
terology (2010) 138:2029–43. doi:10.1053/j.gastro.2010.01.057
4. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions accord-
ing to the human development index (2008-2030): a population-based study.
Lancet Oncol (2012) 13:790–801. doi:10.1016/S1470-2045(12)70211-5
5. Chatenoud L, Bertuccio P, Bosetti C, Malvezzi M, Levi F, Negri E, et al. Trends
in mortality from major cancers in the americas: 1980-2010. Ann Oncol (2014)
25:1843–53. doi:10.1093/annonc/mdu206
6. Arnold M, Karim-Kos HE, Coebergh JW, Byrnes G, Antilla A, Ferlay J, et al.
Recent trends in incidence of five common cancers in 26 European countries
since 1988: analysis of the European cancer observatory. Eur J Cancer (2013).
doi:10.1016/j.ejca.2013.09.002
7. Rutter CM, Johnson EA, Feuer EJ, Knudsen AB, Kuntz KM, Schrag D. Secular
trends in colon and rectal cancer relative survival. J Natl Cancer Inst (2013)
105:1806–13. doi:10.1093/jnci/djt299
8. Renouf DJ, Woods R, Speers C, Hay J, Phang PT, Fitzgerald C, et al. Improve-
ments in 5-year outcomes of stage II/III rectal cancer relative to colon cancer.
Am J Clin Oncol (2013) 36:558–64. doi:10.1097/COC.0b013e318256f5dc
9. Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mor-
tality, survival, and risk factors. Clin Colon Rectal Surg (2009) 22:191–7.
doi:10.1055/s-0029-1242458
10. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer
treatment and survivorship statistics, 2014.CACancer J Clin (2014) 64:252–71.
doi:10.3322/caac.21235
11. Levin TR, Jamieson L, Burley DA, Reyes J, Oehrli M, Caldwell C. Organized
colorectal cancer screening in integrated health care systems. Epidemiol Rev
(2011) 33:101–10. doi:10.1093/epirev/mxr007
12. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al.GLOBO-
CAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base
www.frontiersin.org October 2014 | Volume 2 | Article 210 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stracci et al. Colorectal cancer screening
No. 11. Lyon: International Agency for Research on Cancer (2013). Available
from: http://globocan.iarc.fr
13. Altobelli E, Lattanzi A, Paduano R, Varassi G, di Orio F. Colorectal cancer pre-
vention in Europe: burden of disease and status of screening programs. Prev
Med (2014) 62:132–41. doi:10.1016/j.ypmed.2014.02.010
14. Hill MJ, Morson BC, Bussey HJ. Aetiology of adenoma-carcinoma sequence in
large bowel. Lancet (1978) 1:245–7. doi:10.1016/S0140-6736(78)90487-7
15. Elmunzer BJ, Hayward RA, Schoenfeld PS, Saini SD, Deshpande A, Waljee AK.
Effect of flexible sigmoidoscopy-based screening on incidence and mortality of
colorectal cancer: a systematic review and meta-analysis of randomized con-
trolled trials.PLoSMed (2012) 9:e1001352. doi:10.1371/journal.pmed.1001352
16. Brenner H, Chang-Claude J, Seiler CM, Rickert A, Hoff Meister M. Pro-
tection from colorectal cancer after colonoscopy: a population based, case-
control study.Ann InternMed (2011) 154:22–30. doi:10.7326/0003-4819-154-
1-201101040-00004
17. Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, Qian ZR, et al. Long-term
colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med
(2013) 369:1095–105. doi:10.1056/NEJMoa1301969
18. Ventura L, Mantellini P, Grazzini G, Castiglione G, Buzzoni C, Rubeca T, et al.
The impact of immunochemical faecal occult blood testing on colorectal cancer
incidence. Dig Liver Dis (2014) 46:82–6. doi:10.1016/j.dld.2013.07.017
19. Holme Ø, Bretthauer M, Fretheim A, Odgaard-Jensen J, Hoff G. Flexible sig-
moidoscopy versus faecal occult blood testing for colorectal cancer screening
in asymptomatic individuals. Cochrane Database Syst Rev (2013) 9:CD009259.
doi:10.1002/14651858.CD009259.pub2
20. Whitlock EP, Lin JS, Liles E, Beil TL, Fu R. Screening for colorectal cancer:
a targeted, updated systematic review for the U.S. Preventive Services Task
Force. Ann Intern Med (2008) 149:638–58. doi:10.7326/0003-4819-149-9-
200811040-00245
21. Segnan N, Patnick J, Karsa LV editors.EuropeanGuidelines forQualityAssurance
in Colorectal Cancer Screening and Diagnosis. Luxembourg: Office for Official
Publications of the European Communities (2010).
22. Federici A, Giorgi Rossi P, Borgia P, Bartolozzi F, Farchi S, Gausticchi G. The
immunochemical faecal occult blood test leads to higher compliance than the
guaiac for colorectal cancer screening programmes: a cluster randomized con-
trolled trial. J Med Screen (2005) 12:83–8. doi:10.1258/0969141053908357
23. Kaminski MF, Bretthauer M, Zauber AG, Kuipers EJ, Adami HO, van Ballegooi-
jen M, et al. The NordICC Study: rationale and design of a randomized trial
on colonoscopy screening for colorectal cancer. Endoscopy (2012) 44:695–702.
doi:10.1055/s-0032-1306895
24. Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas Á, et al.
Colonoscopy versus fecal immunochemical testing in colorectal-cancer screen-
ing. N Engl J Med (2012) 366:697–706. doi:10.1056/NEJMoa1108895
25. Robertson DJ. Digestive Diseases Week 2011: VA Cooperative Study #577.
Colonoscopy vs. Fecal Immunological Test in Reducing Mortality from Col-
orectal Cancer (CONFIRM). Available from: http://clinicaltrials.gov/ct2/show/
NCT01239082
26. Pox CP. Controversies in colorectal cancer screening. Digestion (2014)
89:274–81. doi:10.1159/000363287
27. Lansdorp-Vogelaar I, Knudsen AB, Brenner H. Cost-effectiveness of colorec-
tal cancer screening. Epidemiol Rev (2011) 33:88–100. doi:10.1093/epirev/
mxr004
28. Cruzado J, Sánchez FI, Abellán JM, Pérez-Riquelme F, Carballo F. Economic
evaluation of colorectal cancer (CRC) screening. Best Pract Res Clin Gastroen-
terol (2013) 27:867–80. doi:10.1016/j.bpg.2013.09.004
29. Young PE, Womeldorph CM. Colonoscopy for colorectal cancer screening.
J Cancer (2013) 4:217–26. doi:10.7150/jca.5829
30. Hardcastle JD,Chamberlain JO,Robinson MH,Moss SM,Amar SS,Balfour TW,
et al. Randomised controlled trial of faecal-occult-blood screening for colorec-
tal cancer. Lancet (1996) 348:1472–7. doi:10.1016/S0140-6736(96)03386-7
31. Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised
study of screening for colorectal cancer with faecal-occult-blood test. Lancet
(1996) 348:1467–71. doi:10.1016/S0140-6736(96)03430-7
32. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effec-
tiveness of biennial screening for fecal occult blood. J Natl Cancer Inst (1999)
91:434–7. doi:10.1093/jnci/91.5.434
33. Lindholm E, Brevinge H, Haglind E. Survival benefit in a randomized clinical
trial of faecal occult blood screening for colorectal cancer. Br J Surg (2008)
95:1029–36. doi:10.1002/bjs.6136
34. Hewitson P, Glasziou P, Irwig L, Towler B, Watson E. Screening for colorectal
cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst
Rev (2007) 1:CD001216. doi:10.1002/14651858
35. Sinatra MA, St John DJ, Young GP. Interference of plant peroxidases with
guaiac-based fecal occult blood tests is avoidable. Clin Chem (1999) 45:123–6.
36. Pignone M, Campbell MK, Carr C, Phillips C. Meta-analysis of dietary restric-
tion during fecal occult blood testing. Eff Clin Pract (2001) 4:150–6.
37. O’Malley AS, Beaton E, Yabroff K, Abramson R, Mandelblatt J. Patient and
provider barriers to colorectal cancer screening in the primary care safety-net.
Prev Med (2004) 39:56–63. doi:10.1016/j.ypmed.2004.02.022
38. Konrad G. Dietary interventions for fecal occult blood test screening: system-
atic review of the literature. Can Fam Physician (2010) 56:229–38.
39. Duffy MJ, van Rossum LG, van Turenhout ST, Malminiemi O, Sturgeon C,
Lamerz R, et al. Use of faecal markers in screening for colorectal neoplasia:
a European group on tumor markers position paper. Int J Cancer (2011)
128:3–11. doi:10.1002/ijc.25654
40. Young GP. Population-based screening for colorectal cancer: Australian
research and implementation. J Gastroenterol Hepatol (2009) 24(Suppl
3):S33–42. doi:10.1111/j.1440-1746.2009.06069.x
41. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al.
Reducing mortality from colorectal cancer by screening for fecal occult blood.
Minnesota Colon Cancer Control Study. N Engl J Med (1993) 328:1365–71.
doi:10.1056/NEJM199305133281901
42. Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J,
et al. American Cancer Society Colorectal Cancer Advisory Group; US Multi-
Society Task Force; American College of Radiology Colon Cancer Commit-
tee. Screening and surveillance for the early detection of colorectal can-
cer and adenomatous polyps, 2008: a joint guideline from the American
Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and
the American College of Radiology. Gastroenterology (2008) 134:1570–95.
doi:10.1053/j.gastro.2008.02.002
43. Young GP, Sinatra MA, St John DJ. Influence of delay in stool sampling on fecal
occult blood test sensitivity. Clin Chem (1996) 42:1107–8.
44. Zorzi M, Fedeli U, Schievano E, Bovo E, Guzzinati S, Baracco S, et al. Impact
on colorectal cancer mortality of screening programmes based on the faecal
immunochemical test. Gut (2014). doi:10.1136/gutjnl-2014-307508
45. Smith A,Young GP, Cole SR, Bampton P. Comparison of a brush-sampling fecal
immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult
blood test in detection of colorectal neoplasia. Cancer (2006) 107:2152–9.
doi:10.1002/cncr.22230
46. Levi Z, Hazazi R, Rozen P, Vilkin A, Waked A, Niv Y. A quantitative immuno-
chemical faecal occult blood test is more efficient for detecting significant col-
orectal neoplasia than a sensitive guaiac test. Aliment Pharmacol Ther (2006)
23:1359–64. doi:10.1111/j.1365-2036.2006.02898.x
47. Guittet L, Bouvier V, Mariotte N, Vallee JP, Arsène D, Boutreux S, et al. Com-
parison of a guaiac based and an immunochemical faecal occult blood test in
screening for colorectal cancer in a general average risk population. Gut (2007)
56:210–4. doi:10.1136/gut.2006.101428
48. Dancourt V, Lejeune C, Lepage C, Gailliard MC, Meny B, Faivre J. Immuno-
chemical faecal occult blood tests are superior to guaiac-based tests for the
detection of colorectal neoplasms. Eur J Cancer (2008) 44:2254–8. doi:10.1016/
j.ejca.2008.06.041
49. Guittet L, Bouvier V, Mariotte N, Vallee JP, Levillain R, Tichet J, et al. Com-
parison of a guaiac and an immunochemical faecal occult blood test for the
detection of colonic lesions according to lesion type and location. Br J Cancer
(2009) 100:1230–5. doi:10.1038/sj.bjc.6604996
50. van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken
HH, et al. Random comparison of guaiac and immunochemical fecal occult
blood tests for colorectal cancer in a screening population. Gastroenterology
(2008) 135:82–90. doi:10.1053/j.gastro.2008.03.040
51. Rozen P, Levi Z, Hazazi R, Waked A, Vilkin A, Maoz E, et al. Quantitative
colonoscopic evaluation of relative efficiencies of an immunochemical faecal
occult blood test and a sensitive guaiac test for detecting significant colorec-
tal neoplasms. Aliment Pharmacol Ther (2009) 29:450–7. doi:10.1111/j.1365-
2036.2008.03898.x
52. Hol L, van Leerdam ME, van Ballegooijen M, van Vuuren AJ, van Dekken H,
Reijerink JC, et al. Screening for colorectal cancer: randomised trial compar-
ing guaiac-based and immunochemical faecal occult blood testing and flexible
sigmoidoscopy. Gut (2010) 59:62–8. doi:10.1136/gut.2009.177089
Frontiers in Public Health | Epidemiology October 2014 | Volume 2 | Article 210 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stracci et al. Colorectal cancer screening
53. Park DI, Ryu S, Kim YH, Lee SH, Lee CK, Eun CS, et al. Comparison of guaiac-
based and quantitative immunochemical fecal occult blood testing in a popula-
tion at average risk undergoing colorectal cancer screening. Am J Gastroenterol
(2010) 105:2017–25. doi:10.1038/ajg.2010.179
54. Levi Z, Birkenfeld S, Vilkin A, Bar-Chana M, Lifshitz I, Chared M, et al. A
higher detection rate for colorectal cancer and advanced adenomatous polyp
for screening with immunochemical fecal occult blood test than guaiac fecal
occult blood test, despite lower compliance rate. A prospective, controlled,
feasibility study. Int J Cancer (2011) 128:2415–24. doi:10.1002/ijc.25574
55. Rozen P, Comaneshter D, Levi Z, Hazazi R, Vilkin A, Maoz E, et al. Cumulative
evaluation of a quantitative immunochemical fecal occult blood test to deter-
mine its optimal clinical use. Cancer (2010) 116:2115–25. doi:10.1002/cncr.
25012
56. Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical
fecal occult blood tests for colorectal adenoma detection. Ann Intern Med
(2009) 150:162–9. doi:10.7326/0003-4819-150-3-200902030-00005
57. Nakama H, Zhang B, Fattah AS. A cost-effective analysis of the optimum num-
ber of stool specimens collected for immunochemical occult blood screen-
ing for colorectal cancer. Eur J Cancer (2000) 36:647–50. doi:10.1016/S0959-
8049(00)00020-4
58. Castiglione G, Grazzini G, Miccinesi G, Rubeca T, Sani C, Turco P, et al.
Basic variables at different positivity thresholds of a quantitative immuno-
chemical test for faecal occult blood. J Med Screen (2002) 9:99–103. doi:10.
1136/jms.9.3.99
59. Bampton PA, Sandford JJ, Cole SR, Smith A, Morcom J, Cadd B, et al. Interval
faecal occult blood testing in a colonoscopy based screening programme detects
additional pathology. Gut (2005) 54:803–6. doi:10.1136/gut.2004.043786
60. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Sakaguchi K, et al. Sensi-
tivity of immunochemical fecal occult blood test to small colorectal adenomas.
AmJGastroenterol (2007) 102:2259–64. doi:10.1111/j.1572-0241.2007.01404.x
61. Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochem-
ical tests for colorectal cancer. Systematic review and meta-analysis. Ann Intern
Med (2014) 160:171–81. doi:10.7326/M13-1484
62. Cole SR, Young GP, Esterman A, Cadd B, Morcom J. A randomised trial of
the impact of new faecal haemoglobin test technologies on population par-
ticipation in screening for colorectal cancer. J Med Screen (2003) 10:117–22.
doi:10.1258/096914103769011003
63. Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E, et al. A quantitative
immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern
Med (2007) 146:244–55. doi:10.7326/0003-4819-146-4-200702200-00003
64. Grazzini G, Ventura L, Zappa M, Ciatto S, Confortini M, Rapi S, et al.
Influence of seasonal variations in ambient temperatures on performance
of immunochemical faecal occult blood test for colorectal cancer screen-
ing: observational study from the Florence district. Gut (2010) 59:1511–5.
doi:10.1136/gut.2009.200873
65. Hol L, Wilschut JA, van Ballegooijen M, van Vuuren AJ, van der Valk H, Rei-
jerink JC, et al. Screening for colorectal cancer: random comparison of guaiac
and immunochemical faecal occult blood testing at different cut-off levels. Br
J Cancer (2009) 100:1103–10. doi:10.1038/sj.bjc.6604961
66. Fraser CG, Matthew CM, Mowat NA, Wilson JA, Carey FA, Steele RJ. Immuno-
chemical testing of individuals positive for guaiac faecal occult blood test in
a screening programme for colorectal cancer: an observational study. Lancet
Oncol (2006) 7:127–31. doi:10.1016/S1470-2045(05)70473-3
67. Flitcroft KL, Irwig LM, Carter SM, Salkeld GP, Gillespie JA. Colorectal can-
cer screening: why immunochemical fecal occult blood tests may be the best
option. BMC Gastroenterol (2012) 12:183. doi:10.1186/1471-230X-12-183
68. Guittet L, Bouvier V, Guillaume E, Levillain R, Ruiz A, Lantieri O, et al. Col-
orectal cancer screening: why immunochemical faecal occult blood test per-
forms as well with either one or two samples. Dig Liver Dis (2012) 44:694–9.
doi:10.1016/j.dld.2012.03.005
69. Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM,
et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal
cancer: a multicentre randomised controlled trial. Lancet (2010) 375:1624–33.
doi:10.1016/S0140-6736(10)60551-X
70. Segnan N, Armaroli P, Bonelli L, Risio M, Sciallero S, Zappa M, et al. Once-only
sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian
Randomized Controlled Trial-SCORE. J Natl Cancer Inst (2011) 103:1310–22.
doi:10.1093/jnci/djr284
71. Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO,
et al. Colorectal-cancer incidence and mortality with screening flexible sig-
moidoscopy. N Engl J Med (2012) 366:2345–57. doi:10.1056/NEJMoa1114635
72. Holme Ø, Løberg M, Kalager M, Bretthauer M, Hernán MA, Aas E, et al.
Effect of flexible sigmoidoscopy screening on colorectal cancer incidence
and mortality: a randomized clinical trial. JAMA (2014) 312(6):606–15.
doi:10.1001/jama.2014.8266
73. Lieberman DA, Weiss DG. One-time screening for colorectal cancer with com-
bined fecal occult-blood testing and examination of the distal colon. N Engl
J Med (2001) 345:555–60. doi:10.1056/NEJMoa010328
74. Berry DP, Clarke P, Hardcastle JD, Vellacott KD. Randomized trial of the addi-
tion of flexible sigmoidoscopy to faecal occult blood testing for colorectal
neoplasia population screening. Br J Surg (1997) 84:1274–6. doi:10.1002/bjs.
1800840922
75. Rasmussen M, Kronborg O, Fenger C, Jørgensen OD. Possible advantages and
drawbacks of adding flexible sigmoidoscopy to hemoccult-II in screening for
colorectal cancer. A randomized study. Scand J Gastroenterol (1999) 34:73–8.
doi:10.1080/00365529950172862
76. Levin TR, Conell C, Shapiro JA, Chazan SG, Nadel MR, Selby JV. Complications
of screening flexible sigmoidoscopy. Gastroenterology (2002) 123:1786–92.
doi:10.1053/gast.2002.37064
77. Rex DK, Rahmani EY, Haseman JH, Lemmel GT, Kaster S, Buckley JS. Relative
sensitivity of colonoscopy and barium enema for detection of colorectal can-
cer in clinical practice. Gastroenterology (1997) 112:17–23. doi:10.1016/S0016-
5085(97)70213-0
78. Avidan B, Sonnenberg A, Schnell TG, Leya J, Metz A, Sontag SJ. New occurrence
and recurrence of neoplasms within 5 years of a screening colonoscopy. Am J
Gastroenterol (2002) 97:1524–9. doi:10.1111/j.1572-0241.2002.05801.x
79. Pickhardt PJ, Choi JR, Hwang I, Butler JA, Puckett ML, Hildebrandt HA,
et al. Computed tomographic virtual colonoscopy to screen for colorec-
tal neoplasia in asymptomatic adults. N Engl J Med (2003) 349:2191–200.
doi:10.1056/NEJMoa031618
80. Hosokawa O, Shirasaki S, Kaizaki Y, Hayashi H, Douden K, Hattori M. Invasive
colorectal cancer detected up to 3 years after a colonoscopy negative for cancer.
Endoscopy (2003) 35:506–10. doi:10.1055/s-2003-39665
81. Farrar WD, Sawhney MS, Nelson DB, Lederle FA, Bond JH. Colorectal can-
cers found after a complete colonoscopy. Clin Gastroenterol Hepatol (2006)
4:1259–64. doi:10.1016/j.cgh.2006.07.012
82. Bressler B, Paszat LF, Chen Z, Rothwell DM, Vinden C, Rabeneck L. Rates of
new or missed colorectal cancers after colonoscopy and their risk factors: a
population-based analysis. Gastroenterology (2007) 132:96–102. doi:10.1053/j.
gastro.2006.10.027
83. U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Pre-
ventive Services Task Force recommendation statement.Ann InternMed (2008)
149:627–37. doi:10.7326/0003-4819-149-9-200811040-00243
84. Winawer SJ, Zauber AG, Ho MN, O’Brien MJ, Gottlieb LS, Sternberg SS, et al.
Prevention of colorectal cancer by colonoscopic polypectomy. The National
Polyp Study Workgroup. N Engl J Med (1993) 329:1977–81. doi:10.1056/
NEJM199312303292701
85. Citarda F, Tomaselli G, Capocaccia R, Barcherini S, Crespi M, Italian Mul-
ticentre Study Group. Efficacy in standard clinical practice of colonoscopic
polypectomy in reducing colorectal cancer incidence. Gut (2001) 48:812–5.
doi:10.1136/gut.48.6.812
86. Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L.
Association of colonoscopy and death from colorectal cancer. Ann Intern Med
(2009) 150:1–8. doi:10.7326/0003-4819-150-1-200901060-00306
87. Zauber AG, Winawer SJ, O’Brien MJ, Lansdorp-Vogelaar I, van Ballegooijen
M, Hankey BF, et al. Colonoscopic polypectomy and longterm prevention
of colorectal-cancer deaths. N Engl J Med (2012) 366:687–96. doi:10.1056/
NEJMoa1100370
88. Kaminski MF, Regula J, Kraszewska E, Polkowski M, Wojciechowska
U, Didkowska J, et al. Quality indicators for colonoscopy and the risk
of interval cancer. N Engl J Med (2010) 362:1795–803. doi:10.1056/
NEJMoa0907667
89. Brenner H, Hoffmeister M, Arndt V, Stegmaier C, Altenhofen L, Haug U.
Protection from right- and left-sided colorectal neoplasms after colonoscopy:
population-based study. J Natl Cancer Inst (2010) 102:89–95. doi:10.1093/jnci/
djp436
www.frontiersin.org October 2014 | Volume 2 | Article 210 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stracci et al. Colorectal cancer screening
90. Singh H, Nugent Z, Mahmud SM, Demers AA, Bernstein CN. Predictors of
colorectal cancer after negative colonoscopy: a population-based study. Am
J Gastroenterol (2010) 105:663–73. doi:10.1038/ajg.2009.650
91. Rex DK, Bond JH, Winawer S, Levin TR, Burt RW, Johnson DA, et al. Qual-
ity in the technical performance of colonoscopy and the continuous quality
improvement process for colonoscopy: recommendations of the US Multi-
Society Task Force on colorectal cancer.AmJGastroenterol (2002) 97:1296–308.
doi:10.1111/j.1572-0241.2002.05812.x
92. Shapiro JA, Klabunde CN, Thompson TD, Nadel MR, Seeff LC, White A. Pat-
terns of colorectal cancer test use, including CT colonography, in the 2010
National Health Interview Survey. Cancer Epidemiol Biomarkers Prev (2012)
21:895–904. doi:10.1158/1055-9965.EPI-12-0192
93. Pox C, Schmiegel W, Classen M. Current status of screening colonoscopy in
Europe and in the United States. Endoscopy (2007) 39:168–73. doi:10.1055/s-
2007-966182
94. Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal
cancer. CA Cancer J Clin (2009) 59:366–78. doi:10.3322/caac.20038
95. Binefa G, Rodríguez-Moranta F, Teule A, Medina-Hayas M. Colorectal can-
cer: from prevention to personalized medicine. World J Gastroenterol (2014)
20:6786–808. doi:10.3748/wjg.v20.i22.6786
96. Smith RA, Manassaram-Baptiste D, Brooks D, Cokkinides V, Doroshenk M,
Saslow D, et al. Cancer screening in the United States, 2014: a review of current
American Cancer Society guidelines and current issues in cancer screening. CA
Cancer J Clin (2014) 64:30–51. doi:10.3322/caac.21212
97. Yang DX, Gross CP, Soulos PR, Yu JB. Estimating the magnitude of colorectal
cancers prevented during the era of screening: 1976 to 2009. Cancer (2014)
120:2893–901. doi:10.1002/cncr.28794
98. Zapka J, Klabunde CN, Taplin S, Yuan G, Ransohoff D, Kobrin S. Screening
colonoscopy in the US: attitudes and practices of primary care physicians.
J Gen Intern Med (2012) 27:1150–8. doi:10.1007/s11606-012-2051-3
99. Lee CS, Ronan L, O’Morain C, McNamara D. Screening for colorectal cancer:
what fits best? Expert Rev Gastroenterol Hepatol (2012) 6:301–12. doi:10.1586/
egh.12.12
100. Allison JE, Fraser CG, Halloran SP, Young GP. Population screening for col-
orectal cancer means getting FIT: the past, present, and future of colorectal
cancer screening using the fecal immunochemical test for hemoglobin (FIT).
Gut Liver (2014) 8:117–30. doi:10.5009/gnl.2014.8.2.117
101. Hassan C, Giorgi Rossi P, Camilloni L, Rex DK, Jimenez-Cendales B, Ferroni E,
et al. Meta-analysis: adherence to colorectal cancer screening and the detection
rate for advanced neoplasia, according to the type of screening test. Aliment
Pharmacol Ther (2012) 36:929–40. doi:10.1111/apt.12071
102. Brenner H, Chang-Claude J, Jansen L, Knebel P, Stock C, Hoffmeister M.
Reduced risk of colorectal cancer up to 10 years after screening, surveillance,
or diagnostic colonoscopy. Gastroenterology (2014) 146:709–17. doi:10.1053/j.
gastro.2013.09.001
103. Segnan N, Senore C, Andreoni B, Azzoni A, Bisanti L, Cardelli A, et al. Com-
paring attendance and detection rate of colonoscopy with sigmoidoscopy
and FIT for colorectal cancer screening. Gastroenterology (2007) 132:2304–12.
doi:10.1053/j.gastro.2007.03.030
104. Salas D, Vanaclocha M, Ibáñez J, Molina-Barceló A, Hernández V, Cubiella J,
et al. Participation and detection rates by age and sex for colonoscopy versus
fecal immunochemical testing in colorectal cancer screening. Cancer Causes
Control (2014) 25:985–97. doi:10.1007/s10552-014-0398-y
105. Massat NJ, Moss SM, Halloran SP, Duffy SW. Screening and primary preven-
tion of colorectal cancer: a review of sex-specific and site-specific differences.
J Med Screen (2013) 20:125–48. doi:10.1177/0969141313501292
106. Moss SM, Campbell C, Melia J, Coleman D, Smith S, Parker R, et al. Perfor-
mance measures in three rounds of the English bowel cancer screening pilot.
Gut (2012) 61:101–7. doi:10.1136/gut.2010.236430
107. Zorzi M, Fedato C, Grazzini G, Sassoli De’ Bianchi P, Naldoni C, Pendenza
M, et al. Screening for colorectal cancer in Italy, 2010 survey. Epidemiol Prev
(2012) 36(S1):55–77.
108. Jepson R, Clegg A, Forbes C, Lewis R, Sowden A, Kleijnen J. The determinants of
screening uptake and interventions for increasing uptake: a systematic review.
Health Technol Assess (2000) 4(i–vii):1–133. doi:10.3310/hta4140
109. Camilloni L, Ferroni E, Cendales BJ, Pezzarossi A, Furnari G, Borgia P,
et al. Methods to increase participation in organised screening programs: a
systematic review. BMC Public Health (2013) 13:464. doi:10.1186/1471-2458-
13-464
110. Gupta S, Sussman DA, Doubeni CA, Anderson DS, Day L, Deshpande AR,
et al. Challenges and possible solutions to colorectal cancer screening for the
underserved. J Natl Cancer Inst (2014) 106:dju032. doi:10.1093/jnci/dju032
111. Haug U, Rösch T, Hoffmeister M, Katalinic A, Brenner H, Becker N. Implement-
ing anOrganised Colorectal Cancer Screening Programme in Germany: Opportu-
nities and Challenges. Gesundheitswesen (2014). doi:10.1055/s-0034-1377027
112. Boguradzka A, Wiszniewski M, Kaminski MF, Kraszewska E, Mazurczak-Pluta
T, Rzewuska D, et al. The effect of primary care physician counseling on partici-
pation rate and use of sedation in colonoscopy-based colorectal cancer screen-
ing program – a randomized controlled study. Scand J Gastroenterol (2014)
49:878–84. doi:10.3109/00365521.2014.913191
113. Senore C, Ederle A, Benazzato L, Arrigoni A, Silvani M, Fantin A, et al. Offer-
ing people a choice for colorectal cancer screening. Gut (2013) 62:735–40.
doi:10.1136/gutjnl-2011-301013
114. Hol L, Kuipers EJ, van Ballegooijen M, van Vuuren AJ, Reijerink JC, Habbema
DJ, et al. Uptake of faecal immunochemical test screening among nonpartic-
ipants in a flexible sigmoidoscopy screening programme. Int J Cancer (2012)
130:2096–102. doi:10.1002/ijc.26260
115. Fesler A, Jiang J, Zhai H, Ju J. Circulating microRNA testing for the early
diagnosis and follow-up of colorectal cancer patients. Mol Diagn Ther (2014)
18:303–8. doi:10.1007/s40291-014-0089-0
116. Dinh T, Ladabaum U, Alperin P, Caldwell C, Smith R, Levin TR. Health benefits
and cost-effectiveness of a hybrid screening strategy for colorectal cancer. Clin
Gastroenterol Hepatol (2013) 11:1158–66. doi:10.1016/j.cgh.2013.03.013
117. Gralnek IM, Siersema PD, Halpern Z, Segol O, Melhem A, Suissa A, et al. Stan-
dard forward-viewing colonoscopy versus full-spectrum endoscopy: an inter-
national, multicentre, randomised, tandem colonoscopy trial. Lancet Oncol
(2014) 15:353–60. doi:10.1016/S1470-2045(14)70020-8
118. Ahlquist DA, Sargent DJ, Loprinzi CL, Levin TR, Rex DK, Ahnen DJ, et al.
Stool DNA and occult blood testing for screen detection of colorectal neo-
plasia. Ann Intern Med (2008) 149:441–50. doi:10.7326/0003-4819-149-7-
200810070-00004
119. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME. Fecal DNA
versus fecal occult blood for colorectal cancer screening in an average-risk
population. N Engl J Med (2004) 351:2704–14. doi:10.1056/NEJMoa033403
120. Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, et al.
Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med
(2014) 370:1287–97. doi:10.1056/NEJMoa1311194
121. Liotta LA, Ferrari M, Petricoin E. Written in blood. Nature (2003) 425:905.
doi:10.1038/425905a
122. Halligan S, Wooldrage K, Dadswell E, Kralj-Hans I, von Wagner C, Edwards R,
et al. Computed tomographic colonography versus barium enema for diagno-
sis of colorectal cancer or large polyps in symptomatic patients (SIGGAR): a
multicentre randomised trial. Lancet (2013) 381:1185–93. doi:10.1016/S0140-
6736(12)62124-2
123. von Wagner C, Smith S, Halligan S, Ghanouni A, Power E, Lilford RJ, et al.
Patient acceptability of CT colonography compared with double contrast bar-
ium enema: results from a multicentre randomised controlled trial of sympto-
matic patients.EurRadiol (2011) 21:2046–55. doi:10.1007/s00330-011-2154-y
124. Pickhardt PJ, Hassan C, Halligan S, Marmo R. Colorectal cancer: CT colonogra-
phy and colonoscopy for detection-systematic review and meta-analysis. Radi-
ology (2011) 259:393–405. doi:10.1148/radiol.11101887
125. Sosna J, Morrin MM, Kruskal JB, Lavin PT, Rosen MP, Raptopoulos V. CT
colonography of colorectal polyps: a meta-analysis.AJRAmJRoentgenol (2003)
181:1593–8. doi:10.2214/ajr.181.6.1811593
126. Mulhall BP, Veerappan GR, Jackson JL. Meta-analysis: computed tomographic
colonography. Ann Intern Med (2005) 142:635–50. doi:10.7326/0003-4819-
142-8-200504190-00013
127. Rosman AS, Korsten MA. Meta-analysis comparing CT colonography, air
contrast barium enema, and colonoscopy. Am J Med (2007) 120:203–10.
doi:10.1016/j.amjmed.2006.05.061
128. Halligan S, Altman DG, Taylor SA, Mallett S, Deeks JJ, Bartram CI, et al. CT
colonography in the detection of colorectal polyps and cancer: systematic
review, meta-analysis, and proposed minimum data set for study level report-
ing. Radiology (2005) 237:893–904. doi:10.1148/radiol.2373050176
129. Chaparro M, Gisbert JP, del Campo L, Cantero J, Maté J. Accuracy of com-
puted tomographic colonography for the detection of polyps and colorec-
tal tumors: a systematic review and meta-analysis. Digestion (2009) 80:1–17.
doi:10.1159/000215387
Frontiers in Public Health | Epidemiology October 2014 | Volume 2 | Article 210 | 8
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stracci et al. Colorectal cancer screening
130. Pickhardt PJ. Incidence of colonic perforation at CT colonography: review of
existing data and implications for screening of asymptomatic adults. Radiology
(2006) 239:313–6. doi:10.1148/radiol.2392052002
131. Mani A, Napel S, Paik DS, Jeffrey RB Jr., Yee J, Olcott EW, et al. Com-
puted tomography colonography: feasibility of computer-aided polyp detec-
tion in a first reader paradigm. J Comput Assist Tomogr (2004) 28:318–32.
doi:10.1097/00004728-200405000-00003
132. Iussich G, Correale L, Senore C, Hassan C, Segnan N, Campanella D, et al.
Computer-aided detection for computed tomographic colonography screen-
ing. Invest Radiol (2014) 49:173–82. doi:10.1097/RLI.0000000000000009
133. Stoop EM, de Haan MC, de Wijkerslooth TR, Bossuyt PM, van Ballegooijen
M, Nio CY, et al. Participation and yield of colonoscopy versus non-cathartic
CT colonography in population-based screening for colorectal cancer: a ran-
domised controlled trial. Lancet Oncol (2012) 13:55–64. doi:10.1016/S1470-
2045(11)70283-2
134. Pickhardt PJ, Hanson ME, Vanness DJ, Lo JY, Kim DH, Taylor AJ, et al. Unsus-
pected extracolonic findings at screening CT colonography: clinical and eco-
nomic impact. Radiology (2008) 249:151–9. doi:10.1148/radiol.2491072148
135. Sali L, Grazzini G, Carozzi F, Castiglione G, Falchini M, Mallardi B, et al.
Screening for colorectal cancer with FOBT, virtual colonoscopy and optical
colonoscopy: study protocol for a randomized controlled trial in the Florence
district (SAVE study). Trials (2013) 14:74. doi:10.1186/1745-6215-14-74
136. Regge D, Iussich G, Senore C, Correale L, Hassan C, Bert A, et al. Population
screening for colorectal cancer by flexible sigmoidoscopy or CT colonogra-
phy: study protocol for a multicenter randomized trial. Trials (2014) 15:97.
doi:10.1186/1745-6215-15-97
137. Sali L, Falchini M, Bonanomi AG, Castiglione G, Ciatto S, Mantellini P,
et al. CT colonography after incomplete colonoscopy in subjects with pos-
itive faecal occult blood test. World J Gastroenterol (2008) 14:4499–504.
doi:10.3748/wjg.14.4499
138. Van Gossum A, Munoz-Navas M, Fernandez-Urien I, Carretero C, Gay G, Del-
vaux M,et al. Capsule endoscopy versus colonoscopy for the detection of polyps
and cancer. N Engl J Med (2009) 361:264–70. doi:10.1056/NEJMoa0806347
139. Riccioni ME, Urgesi R, Cianci R, Bizzotto A, Spada C, Costamagna
G. Colon capsule endoscopy: advantages, limitations and expectations.
Which novelties? World J Gastrointest Endosc (2012) 4:99–107. doi:10.4253/
wjge.v4.i4.99
140. Eliakim R,Yassin K, Niv Y, Lachter J, Gal E, Sapoznikov B, et al. Prospective mul-
ticenter performance evaluation of the second-generation colon capsule com-
pared with colonoscopy. Endoscopy (2009) 41:1026–31. doi:10.1055/s-0029-
1215360
141. Spada C, Hassan C, Munoz-Navas M, Neuhaus H, Deviere J, Fockens P, et al.
Second-generation colon capsule endoscopy compared with colonoscopy.Gas-
trointest Endosc (2011) 74:581–9. doi:10.1016/j.gie.2011.03.1125
142. Singhal S, Nigar S, Paleti V, Lane D, Duddempudi S. Bowel preparation regi-
mens for colon capsule endoscopy: a review. Therap Adv Gastroenterol (2014)
7:115–22. doi:10.1177/1756283X13504730
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 28 August 2014; paper pending published: 14 September 2014; accepted: 10
October 2014; published online: 27 October 2014.
Citation: Stracci F, Zorzi M and Grazzini G (2014) Colorectal cancer screening: tests,
strategies, and perspectives. Front. Public Health 2:210. doi: 10.3389/fpubh.2014.00210
This article was submitted to Epidemiology, a section of the journal Frontiers in Public
Health.
Copyright © 2014 Stracci, Zorzi andGrazzini. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use, dis-
tribution or reproduction in other forums is permitted, provided the original author(s)
or licensor are credited and that the original publication in this journal is cited, in
accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
www.frontiersin.org October 2014 | Volume 2 | Article 210 | 9
